The Ebola virus outbreak in Western Africa dominated lots of the stories in 2014. The highly communicable pathogen spreads swiftly and kills over half of those who become infected, leading to major panics across multiple continents. While the vast majority of the dead are in Africa, health employees did bring the pathogen home to other states and continents.
For all of the bad news and focus on doomsday scenarios on what the pathogen could do, there are essentially dome commercial benefits of Ebola virus outbreaks. The industrial benefits principally breakdown between non profit or government groups and for-profit biotechnology corporations.
Central authority or aid setups like the Red Cross or the CDC tend to see increases in funding in events like these. The economic advantages to them are direct and help out those on the ground suffering or helping and containing an outburst.
This containment keeps commercial disruption when funding is adequate to turn the tide of an outbreak.
The longer term economic benefits of Ebola virus outbursts are biotech corporations working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale medical tests.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications prove to be of value.
While the 2014 Ebola break out is first to have captured worldwide attention as much as it probably did, it was barely the 1st breakout. Others have occurred, and more will happen in the future. Any business that has an Ebola drug or vaccine on the market that proves effective can be sure to see an increase in business in the future.
For all of the bad news and focus on doomsday scenarios on what the pathogen could do, there are essentially dome commercial benefits of Ebola virus outbreaks. The industrial benefits principally breakdown between non profit or government groups and for-profit biotechnology corporations.
Central authority or aid setups like the Red Cross or the CDC tend to see increases in funding in events like these. The economic advantages to them are direct and help out those on the ground suffering or helping and containing an outburst.
This containment keeps commercial disruption when funding is adequate to turn the tide of an outbreak.
The longer term economic benefits of Ebola virus outbursts are biotech corporations working on vaccines or drugs that might improve survival rates of those infected with Ebola. One such firm is Tekmira, that has been given blessings by the FDA to widen testing on in its experimental Ebola drug for bigger scale medical tests.
Sarepta Therapeutics, Nanoviricides and BioCryst Pharmaceuticals are other biotech outfits that might see increased business in the future if their own Ebola drugs and medications prove to be of value.
While the 2014 Ebola break out is first to have captured worldwide attention as much as it probably did, it was barely the 1st breakout. Others have occurred, and more will happen in the future. Any business that has an Ebola drug or vaccine on the market that proves effective can be sure to see an increase in business in the future.
About the Author:
my name is alfred obi I've been a biological scientist for years educating individuals on ebola virus disease update and ebola virus disease which has influenced most nations in africa feel free to visit my site for your free protecting gear on ebola thanks.
Nenhum comentário:
Postar um comentário